Cpg oligodeoxyribonucleotide and use thereof in vaccine adjuvant

By combining CpG oligodeoxyribonucleotides with various adjuvants, the problem of poor efficacy of existing vaccine adjuvants in recombinant protein vaccines has been solved, resulting in a safer and more effective immune response, suitable for vaccines against a variety of infectious diseases.

WO2026085700A1PCT designated stage Publication Date: 2026-04-30NANJING JSIAMA BIOPHARMACEUTICALS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO Β· WO
Patent Type
Applications
Current Assignee / Owner
NANJING JSIAMA BIOPHARMACEUTICALS LTD
Filing Date
2024-10-22
Publication Date
2026-04-30

AI Technical Summary

Technical Problem

The application of existing CpG ODN as a vaccine adjuvant is still relatively limited, especially in recombinant protein vaccines where it is ineffective and has toxic side effects. There is a need to develop safer and more effective adjuvant combinations to enhance the immune response.

Method used

It provides combinations of CpG oligodeoxyribonucleotides with various other types of adjuvants, including aluminum adjuvants, squalene oil-in-water adjuvants, ISA adjuvants, AS series adjuvants, etc., to form new adjuvant combinations, activate the immune system, and enhance humoral and cellular immune responses.

Benefits of technology

It significantly improves the immune efficacy of vaccines, especially cellular immunity, while reducing side effects, and is suitable for the prevention or treatment of viral, bacterial, fungal, and parasitic infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024126333_30042026_PF_FP_ABST
    Figure CN2024126333_30042026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a CpG oligodeoxyribonucleotide capable of boosting body immunity, a combination thereof with an additional adjuvant, and the use of the CpG adjuvant or a combination thereof in various vaccine compositions. The CpG, either alone as an adjuvant or in combination with commercially available adjuvants, has the advantages of significant earlier manifestation of immune effects, immune effect improvement, a longer duration of immune protection effects, fewer potential allergic reactions, etc. and is superior to commercially available vaccine adjuvants or adjuvant systems, and is an excellent vaccine adjuvant or effective component in vaccine adjuvant systems.
Need to check novelty before this filing date? Find Prior Art